83877-88-7 Usage
Description
1-benzyl-3-bromo-4-piperidone hydrobromide is a chemical compound derived from piperidone, featuring a benzyl group and a bromine atom in its molecular structure. This heterocyclic compound is known for its unique pharmacological properties and potential applications in the pharmaceutical industry. The hydrobromide salt form of the compound improves its water solubility and bioavailability, making it a promising candidate for drug development.
Uses
Used in Pharmaceutical Industry:
1-benzyl-3-bromo-4-piperidone hydrobromide is used as a potential therapeutic agent for various conditions due to its unique pharmacological properties. The presence of a benzyl group and a bromine atom in its molecular structure contributes to its potential as a drug candidate.
1-benzyl-3-bromo-4-piperidone hydrobromide is used as a compound with improved water solubility and bioavailability in pharmaceutical formulations, thanks to its hydrobromide salt form. This enhances its suitability for drug development and administration.
Research on 1-benzyl-3-bromo-4-piperidone hydrobromide continues to explore its potential applications in the pharmaceutical industry, aiming to develop new drugs that can address various medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 83877-88-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,3,8,7 and 7 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 83877-88:
(7*8)+(6*3)+(5*8)+(4*7)+(3*7)+(2*8)+(1*8)=187
187 % 10 = 7
So 83877-88-7 is a valid CAS Registry Number.
InChI:InChI=1/C12H14BrNO.BrH/c13-11-9-14(7-6-12(11)15)8-10-4-2-1-3-5-10;/h1-5,11H,6-9H2;1H
83877-88-7Relevant articles and documents
GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
-
Page/Page column 121, (2010/02/13)
The invention relates to guanidine compounds of general formula (I), corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and pharmaceutically acceptable salts thereof. The invention further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors in order to treat diseases modulated by 5-HT5 receptor activity, especially treat neurodegenerative and neuropsychiatric disorders and the signs, symptoms, and malfunctions associated therewith.